← Leaderboards
Rosa Maria Diaz
Vyriad, Inc.
$979,046
Attributed
$2,318,623
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–19$2M$1.5M$1M$500K$0
'17
'18
'19
Funding mix
By agency
NIH$2,318,623 · 2
By mechanism
R44$2,318,623 · 2
Top collaborators
- Alex A Adjei3 shared
- Bradley C. Leibovich2 shared
- Lukkana Suksanpaisan2 shared
Most similar at Vyriad, Inc.
Same institution · by research overlap
- Bradley C. Leibovich$360,531
- Shruthi Naik$866,638
- Luke O. Russell$866,638
Others in their field
Other Emerging Leaders on “Neoplastic Cell”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Tina Garyantes · Linnaeus Therapeutics, Llc$6,999,960
- Zachary Scott Morris · University Of Wisconsin-Madison$6,108,830
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$6,006,178
- Gordon M Ringold · Quadriga Biosciences, Inc.$5,755,369
- Himisha Beltran · Dana-Farber Cancer Inst$5,409,904
Research focus
Neoplastic CellSafetyImmune ResponseMonitorOncolytic VirotherapyResponseDisease ProgressionImmune Checkpoint InhibitorIntravenousMediatingOncolyticDoseQuality Of LifeEngineeringClinicClinical TrialsCancer EtiologyImmuneImmunotherapyCessation Of LifeMalignant NeoplasmsMeasurableEffective TherapySafety And Feasibility
Grant awards (5)
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$950,045
R44 · FY2019 · CA · contact PI
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$108,000
R44 · FY2019 · CA · contact PI
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER$924,838
R44 · FY2018 · CA · contact PI
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors$178,985
R44 · FY2018 · CA · contact PI
INTRAVESICAL ONCOLYTIC THERAPY FOR BLADDER CANCER$156,755
R44 · FY2017 · CA · contact PI